Optimization of percutaneous biopsy for diagnosis and pretreatment risk assessment of neuroblastoma
Overman, Richard E.; Kartal, Tanvi T.; Cunningham, Aaron J.; Fialkowski, Elizabeth A.; Naik‐mathuria, Bindi J.; Vasudevan, Sanjeev A.; Malek, Marcus M.; Kalsi, Ranjeet; Le, Hau D.; Stafford, Linda Cherney; Lautz, Timothy B.; Many, Benjamin T.; Jones, Rachel E.; Bütter, Andreana; Davidson, Jacob; Williams, Andrew; Dasgupta, Roshni; Lewis, Jana; Troutt, Misty; Aldrink, Jennifer H.; Mansfield, Sara A.; Lal, Dave R.; Xiao, Jerry; Meyers, Rebecka L.; Short, Scott S.; Newman, Erika A.
2020-05
Citation
Overman, Richard E.; Kartal, Tanvi T.; Cunningham, Aaron J.; Fialkowski, Elizabeth A.; Naik‐mathuria, Bindi J. ; Vasudevan, Sanjeev A.; Malek, Marcus M.; Kalsi, Ranjeet; Le, Hau D.; Stafford, Linda Cherney; Lautz, Timothy B.; Many, Benjamin T.; Jones, Rachel E.; Bütter, Andreana ; Davidson, Jacob; Williams, Andrew; Dasgupta, Roshni; Lewis, Jana; Troutt, Misty; Aldrink, Jennifer H.; Mansfield, Sara A.; Lal, Dave R.; Xiao, Jerry; Meyers, Rebecka L.; Short, Scott S.; Newman, Erika A. (2020). "Optimization of percutaneous biopsy for diagnosis and pretreatment risk assessment of neuroblastoma." Pediatric Blood & Cancer 67(5): n/a-n/a.
Abstract
BackgroundImage- guided percutaneous core needle biopsy (PCNB) is increasingly utilized to diagnose solid tumors. The objective of this study is to determine whether PCNB is adequate for modern biologic characterization of neuroblastoma.ProcedureA multi- institutional retrospective study was performed by the Pediatric Surgical Oncology Research Collaborative on children with neuroblastoma at 12 institutions over a 3- year period. Data collected included demographics, clinical details, biopsy technique, complications, and adequacy of biopsies for cytogenetic markers utilized by the Children’s Oncology Group for risk stratification.ResultsA total of 243 children were identified with a diagnosis of neuroblastoma: 79 (32.5%) tumor excision at diagnosis, 94 (38.7%) open incisional biopsy (IB), and 70 (28.8%) PCNB. Compared to IB, there was no significant difference in ability to accurately obtain a primary diagnosis by PCNB (95.7%Â vs 98.9%, PÂ =Â .314) or determine MYCN copy number (92.4%Â vs 97.8%, PÂ =Â .111). The yield for loss of heterozygosity and tumor ploidy was lower with PCNB versus IB (56.1%Â vs 90.9%, PÂ <Â .05; and 58.0%Â vs. 88.5%, PÂ <Â .05). Complications did not differ between groups (2.9 % vs 3.3%, PÂ =Â 1.000), though the PCNB group had fewer blood transfusions and lower opioid usage. Efficacy of PCNB was improved for loss of heterozygosity when a pediatric pathologist evaluated the fresh specimen for adequacy.ConclusionsPCNB is a less invasive alternative to open biopsy for primary diagnosis and MYCN oncogene status in patients with neuroblastoma. Our data suggest that PCNB could be optimized for complete genetic analysis by standardized protocols and real- time pathology assessment of specimen quality.Publisher
Wiley Periodicals, Inc.
ISSN
1545-5009 1545-5017
Other DOIs
Types
Article
Metadata
Show full item recordCollections
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.